# Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors

> **NCT07349160** · EARLY_PHASE1 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 36 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Metabolically Armed TIL cells.

## Key facts

- **NCT ID:** NCT07349160
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-10
- **Primary completion:** 2027-03-15
- **Final completion:** 2028-01-20
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07349160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07349160, "Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT07349160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*